Kura Oncology (KURA) Accumulated Expenses (2010 - 2026)

Kura Oncology (KURA) has 17 years of Accumulated Expenses data on file, last reported at $45.5 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 533.85% year-over-year to $45.5 million in Q1 2026; TTM through Mar 2026 was $45.5 million, a 533.85% increase from a year earlier, with the FY2025 full-year figure at $22.4 million, down 53.86% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $45.5 million, up from $22.4 million in the prior quarter.
• Over the last five years, Accumulated Expenses for KURA reached as high as $48.5 million in Q4 2024 and fell as low as $4.5 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $14.0 million across 5 years, with a median of $9.1 million in 2023.
• Across the five-year window, Accumulated Expenses sank 53.86% in 2025 and jumped 533.85% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $10.3 million in 2022, then grew by 27.7% to $13.2 million in 2023, then soared by 268.62% to $48.5 million in 2024, then sank by 53.86% to $22.4 million in 2025, then surged by 103.23% to $45.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $45.5 million in Q1 2026, $22.4 million in Q4 2025, and $14.6 million in Q3 2025.